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Abstract 29 
 30 
Background 31 
Chemotherapy-induced premature ovarian insufficiency (POI) impacts fertility and other 32 
aspects of women’s health. The OPTION trial tested whether administration of a gonadotropin 33 
hormone releasing hormone (GnRH) agonist during chemotherapy for early breast cancer 34 
reduced the risk of POI. 35 
 36 
Patients and Methods 37 
This was a prospective, randomized, parallel group study of the GnRH agonist goserelin 38 
administered before and during chemotherapy for breast cancer  with stage I-IIIB disease. The 39 
primary outcome was amenorrhoea between 12 and 24 months after randomization, supported 40 
by elevated follicle stimulating hormone (FSH) concentrations to give an additional analysis as 41 
rate of POI. 42 
 43 
Results 44 
A total of 227 patients were randomized and the primary analysis was conducted on 202 45 
patients. Goserelin reduced the prevalence of amenorrhoea between 12 and 24 months to 46 
22% vs 38% in the control group (P=0.015) and the prevalence of POI to 18.5% vs 34.8% in 47 
the control group (P=0.048). FSH concentrations were also lower in all women treated with 48 
goserelin at both 12 and 24 months (P = 0.027, P = 0.001 respectively). The effect of goserelin 49 
was not statistically significant in women >40 years. Assessment of the ovarian reserve using 50 
anti-Müllerian hormone (AMH) showed a marked fall in both groups during treatment to median 51 
values of 5% of pretreatment levels in the control group and 7% in the goserelin group, which 52 
were not significantly different between groups.  53 
 54 
Conclusion 55 
 3 
This study shows that goserelin reduced the risk of POI in women treated with chemotherapy 56 
for early breast cancer, with particular efficacy in women aged ≤40 years old.  The degree of 57 
ovarian protection also seems limited and the clinical significance for fertility and longer-term 58 
prevention of estrogen deficiency-related outcomes needs to be determined.   59 
 60 
Trial registration: EudraCT 2004-000133-11 61 
 62 
Key message 63 
This RCT of GnRH agonist administration during chemotherapy for early breast cancer for 64 
ovarian protection showed a benefit in women aged under 40 years, but with no detected 65 
benefit in older women.  The use of a biomarker of the ovarian reserve indicated that the 66 
amount of ovarian function preserved by this approach may be small. 67 
  68 
 4 
Introduction 69 
 70 
The improved survival of women with early breast cancer in recent years [1] has led to an 71 
increased interest in the long term consequences of treatment. Amongst these, ovarian toxicity 72 
from chemotherapy is important in younger women, as it may result in loss of fertility and early 73 
menopause (premature ovarian insufficiency, POI) with consequent increased risk of a range 74 
of adverse health effects including menopausal symptoms, osteoporosis, sexual dysfunction, 75 
cardiovascular disease and loss of neurological function [2]. 76 
A number of observational studies have suggested a benefit from GnRH agonist suppression 77 
of ovarian function, but the data from randomized controlled trials (RCTs) remain mixed [3-7]. 78 
The most recent substantial RCT in women with breast cancer [8] found evidence of reduced 79 
risk of ovarian failure with goserelin treatment during chemotherapy, and meta-analyses also 80 
report varying results [9, 10]. Trials in women with Hodgkin lymphoma also report varying results 81 
[11, 12]. 82 
 83 
Recall of menses may be unreliable unless based on a daily diary, and while amenorrhoea is 84 
clear, infrequent or irregular menses may indicate incipient POI. This trial was set up to 85 
establish whether the use of goserelin in women who require chemotherapy for operable 86 
hormone-insensitive breast cancer or for whom ovarian suppression is not considered a 87 
necessary part of treatment, may reduce the risk of POI. This primary outcome was the 88 
prevalence of amenorrhoea at 12-24 months, secondarily combined with elevated follicle-89 
stimulation hormone [FSH] concentration giving the prevalence of POI.  90 
Anti-Müllerian hormone (AMH) is also a valid and valuable marker of ovarian follicle reserve 91 
[13].  Pre-treatment AMH has been suggested to predict long term ovarian function following 92 
chemotherapy for early breast cancer, and post-treatment concentrations are an indicator of 93 
the remaining ovarian reserve in women who maintain menstrual function, thus providing a 94 
quantitative estimate of the degree of ovarian protection [14, 15]. 95 
 96 
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Patients and Methods 97 
Premenopausal patients with histologically confirmed breast cancer who were to receive 98 
adjuvant or neo-adjuvant chemotherapy were eligible for ‘OPTION’. All patients gave informed 99 
consent and the study received Ethical Committee approval (South West Multi-centre Research 100 
Ethics Committee, ref MREC/03/6/90).  The original protocol restricted the entry of patients to 101 
those with ER-negative tumors only, but patients with ER-positive tumors for whom the 102 
investigator did not deem ovarian suppression necessary as part of the treatment were 103 
subsequently allowed entry to the trial after a protocol amendment. The breast cancers could 104 
be up to stage IIIB (T1-T4 with N0-2) and complete excision of the tumor before adjuvant 105 
chemotherapy or planned after neoadjuvant therapy was required. The patients had to be pre-106 
menopausal (defined as regular menses in the 12 months prior to chemotherapy). Metastatic 107 
disease was an exclusion criterion. Patients who had had prior chemotherapy or endocrine 108 
therapy were ineligible. Chemotherapy regimens included 6-8 cycles of cyclophosphamide 109 
and/or anthracycline-containing regimens with or without a taxane. Patients were randomized 110 
to receive a 3.6mg goserelin implant or nothing starting at least one week, and preferably two 111 
weeks, prior to the start of the chemotherapy treatment, and continuing goserelin 3-4 weekly 112 
until the end of the chemotherapy treatment. Chemotherapy had to start within 8 weeks of 113 
definitive surgery. Radiotherapy was as per standard protocol for each centre. 114 
 115 
Randomization was centrally performed by telephone to the trial center, eligibility was 116 
confirmed verbally, and treatment was allocated by computer-generated lists. Pre-treatment 117 
evaluation included history and physical examination, haematology and biochemistry profiles, 118 
chest x-ray, electrocardiograph, and measurements of estradiol, FSH, and luteinizing hormone 119 
(LH) which were performed locally; serum was also stored for later measurement of AMH which 120 
was performed centrally using the Roche Elecsys automated assay. 121 
 122 
 6 
Patients were followed-up 6-monthly for 2 years and then 12-monthly for a further 3 years. 123 
Hormone levels were checked at cycle 3, after the final cycle, then at 9 months, 12 months, 124 
then annually. A menstruation diary was kept for 24 months from the start of chemotherapy. 125 
 126 
Statistical analysis 127 
The primary outcome was the rate of amenorrhea ie no menses between 12 and 24 months 128 
after randomization, also combined with elevated FSH concentrations to give rate of POI. For 129 
the sample size calculation, it was assumed that the rate of amenorrhea would be 40% in the 130 
40 years and under age-group and 80% in the over 40 age-group. At the time of conception of 131 
the trial, two uncontrolled studies had suggested that goserelin might reduce the rate of 132 
premature menopause to 20%. A one-sided test with 5% false-positive rate was used to 133 
calculate the sample size to give an 80% chance of detecting an absolute reduction from 40% 134 
to 20% in the 40 years and under group and from 80% to 55% in the older age group. It was 135 
intended to recruit a total of 250 patients and allowing for a 15% loss to follow-up. 136 
Randomization was stratified by age (aged 40 years or younger and those over 40 years) and 137 
by center. 138 
 139 
Analysis of binary endpoints was conducted using a two-sided Fisher’s Exact test. 140 
Comparisons of the hormone concentrations between treatment groups were by the Mann-141 
Whitney test. An exploratory logistic regression analysis was performed to assess the 142 
predictive value of age, total cyclophosphamide dose and baseline AMH for amenorrhoea. To 143 
ensure an intention to treat analysis where the primary end-point data were unobtainable, two 144 
alternative imputations were made: 145 
1. Best case: All patients with missing information were assumed not to have experienced 146 
amenorrhea (regardless of treatment arm). 147 
2. Worst case: All patients with missing information were assumed to have experienced 148 
amenorrhea (regardless of treatment arm). 149 
 150 
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Results 151 
 152 
227 patients were randomized between 26 August 2004 and the end of December 2009.  Of 153 
these, 3 in each arm were omitted from this analysis because they had died within 24 months 154 
of randomization and had therefore unknown menstrual status at 24 months. The age 155 
distribution, chemotherapy regimens and ER status for these 221 patients are described in 156 
Table 1, and did not differ between the 2 groups. For a further 19 patients (11 in the control 157 
arm and 8 in the intervention arm), menstrual status during the interval between the 12 month 158 
follow up visit and the 24 month follow up visit could not be determined from the data available.  159 
The primary analysis was therefore conducted on 202 patients (figure 1).   160 
 161 
Primary outcome 162 
The prevalence of amenorrhoea during chemotherapy was, as expected, much higher in the 163 
goserelin group (97.9% vs 63.5%, P<0.0001). By 12 months menses had resumed in many 164 
women, in both groups.  165 
 166 
The main outcome of this trial showed a difference in the prevalence of amenorrhoea between 167 
12 and 24 months, being 22% in the goserelin group vs 38% in the control group (P=0.015, 168 
table 2). After imputing missing data both as worst case (all with amenorrhoea) or best case 169 
(none with amenorrhoea) scenarios, there remained significant differences between groups, 170 
with reduced prevalence of amenorrhoea in the goserelin group (table 2). This apparent 171 
protective effect of goserelin was further assessed using the definition of POI ie amenorrhoea 172 
with elevated FSH concentrations using a FSH cutoff of 25IU/L [16]. The prevalence of POI in 173 
the goserelin group was 18.5% vs 34.8% in the control group (P=0.048), thus closely mirroring 174 
the amenorrhoea results. 175 
 176 
Given the likely importance of age in determining risk of chemotherapy-related amenorrhoea, 177 
groups were stratified by age, using a cutoff of 40 years. This analysis showed a protective 178 
 8 
effect of goserelin on both the prevalence of amenorrhoea alone and on POI (amenorrhoea 179 
plus high FSH) in women aged ≤40 (amenorrhoea: 10.0% vs 25.4%, P = 0.032; POI: 2.6% vs 180 
20.0%, P=0.038). The effect was less clear and not statistically significant in women >40 years 181 
(amenorrhoea: 42.9% vs 54.2%, P = 0.376; POI: 42.3% vs 47.2%, p=0.798). 182 
 183 
Nine pregnancies occurred in women in the goserelin group (including 2 pregnancies each for 184 
2 women) and 6 in the control group (including 2 pregnancies in one woman). A total of 24 185 
deaths occurred, 9 in the goserelin group and 15 in the control group. 186 
 187 
Hormonal evaluations 188 
The control group showed a fall in estradiol concentrations during and following chemotherapy, 189 
with resultant rises in FSH and LH (figure 2).  The goserelin group showed the expected 190 
significant reductions in LH, FSH and E2 during treatment (figure 2), with the estradiol changes 191 
also reflecting the effect of chemotherapy. Consistent with the reduced prevalence of POI in 192 
the treated group, FSH concentrations were lower than in the control group at both 12 and 24 193 
months (P = 0.027, P = 0.001 respectively). 194 
There was a marked fall in AMH in both groups during treatment to median values of 195 
approximately 5% of pretreatment levels in the control group and to 7% in the goserelin group 196 
(figure 2), changes that were not significantly different between groups.  197 
 198 
Logistic regression analysis was performed to assess the predictive value of factors associated 199 
with amenorrhoea (supplementary table 1).  Pretreatment AMH was shown to be a predictor 200 
of post-treatment amenorrhoea (odds ratio 0.43, 95% confidence interval [CI] 0.23-0.80, 201 
P=0.01), as was age (OR 1.28, CI 1.18-1.39, P<0.001), although after adjustment for age, the 202 
effect of pretreatment AMH was no longer significant. Total cyclophosphamide dose was not 203 
predictive (OR 1.15, CI 0.99-1.34, P = 0.07). 204 
 205 
Discussion 206 
 9 
Our results demonstrate that the use of the GnRH analogue goserelin provides some 207 
protection of ovarian function during chemotherapy for early breast cancer. The effect appears 208 
age-dependent, being less clear for women who are older than 40. It may be that the relative 209 
sample sizes in the two age cohorts accounts for some of this difference, accentuated by the 210 
slight randomization imbalance in the older age group. Results of AMH analysis, albeit only in 211 
a subgroup, demonstrated a very marked fall in this marker of the ovarian reserve in all women, 212 
and thus any protection of ovarian reserve is likely to be small. 213 
 214 
There remains uncertainty concerning the efficacy or otherwise of trying to protect ovarian 215 
function from chemotherapy with GnRH-agonist mediated gonadotrophin suppression [17].  216 
The present data are comparable with the results of some but not all RCTs of GnRH analogue 217 
treatment for the prevention of ovarian toxicity from chemotherapy. Two recent meta-analyses 218 
came to different conclusions: one, of 12 RCTs including 1231 breast cancer patients indicated 219 
that GnRH analogue treatment reduced the risk of POI (OR 0.36, 95% CI 0.23-0.57) although 220 
significant heterogeneity between study results was identified [10]. The second, of 10 trials 221 
including 907 women, concluded that GnRH analogues did not increase the proportion of 222 
women with ovarian function after chemotherapy with a risk ratio of 1.12, 95% CI 0.99-1.27 [9]. 223 
Additionally, GnRH analogue use in women receiving chemotherapy for lymphoma show 224 
inconsistent results [11, 12].  The use of GnRH analogues to protect ovarian function has 225 
however been endorsed by the 2015 St Gallen International Consensus Panel [18] and for 226 
women with hormone receptor negative breast cancer in the guidelines of the National 227 
Comprehensive Cancer Network. This study provides substantial additional confidence in this 228 
effect, being the second largest trial reported, but suggests that any benefits are largely 229 
confined to women aged <40 years. 230 
 231 
The mechanism whereby GnRH analogues might provide ovarian protection is unclear.. Loss 232 
of growing follicles due to the effects of chemotherapy may additionally remove local inhibitory 233 
influences on the activation of growth of primordial follicles, thus accelerating depletion of the 234 
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ovarian reserve [19]. There are also both mouse and non-human primate experimental data 235 
indicating a protective effect of GnRH analogues [20, 21] . 236 
 237 
In this and previous similar trials the primary outcome measure has been ovarian function as 238 
revealed by amenorrhoea or POI. These measures do not assess loss of the follicle pool within 239 
the ovary. AMH is a marker of the number of small growing follicles in the ovary, and indirectly 240 
reflects the number of primordial follicles (the ‘ovarian reserve’) [13]. In women with breast 241 
cancer, pretreatment AMH (with age) predicts remaining ovarian function after chemotherapy 242 
[15]. Post-treatment AMH indicates the degree of loss of ovarian reserve [14, 22] as women 243 
who retain ovarian function after chemotherapy are still likely to experience an early 244 
menopause [23]. Analysis of AMH post chemotherapy may be of value in predicting remaining 245 
reproductive lifespan.  The degree of fall in AMH shown here highlights the magnitude of the 246 
ovarian damage even in those without POI, with AMH at 2 years being reduced by 95% in the 247 
control group and by 97% in the goserelin group, although sample collection was incomplete. 248 
Thus the amount of 'saved' ovarian function is modest, but may be of clinical consequence 249 
particularly in younger women where it might allow an increased opportunity for fertility. Longer-250 
term benefits from any reduction in the consequences of estrogen deficiency have yet to be 251 
investigated. 252 
 253 
Age and AMH were predictive of amenorrhea, the latter not being significant when adjusted for 254 
age. This is consistent with previous analyses of AMH as a predictor of post-chemotherapy 255 
ovarian function [15], and the importance of age in that context [24, 25]. This supports the 256 
concept that the size of an individual woman’s ovarian reserve as well as her age determines 257 
her risk of POI following chemotherapy. 258 
 259 
Additional data from a bone sub-study of this trial also suggested that goserelin provides some 260 
degree of ovarian protection from chemotherapy. Although the addition of goserelin to 261 
chemotherapy increased bone turnover during treatment, the return of bone biomarkers to the 262 
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normal range after cessation of treatment was more frequent with goserelin and suggested 263 
that it may offer sufficient ovarian protection against chemotherapy-induced POI to negate the 264 
long term altered bone turnover associated with POI [26].  265 
 266 
Although the number of recurrences in our study are too few for meaningful comparison, the 267 
results of other trials that included mostly hormone-receptor positive breast cancer have been 268 
encouraging in respect of safety and efficacy [10], an important observation given the apparent 269 
survival benefit associated with chemotherapy-induced amenorrhoea in women with estrogen 270 
receptor positive breast cancer [27]. 271 
 272 
We conclude that the impact of using a GnRH analogue moderately reduces the risk of POI 273 
induced by standard adjuvant chemotherapy for early breast cancer in young women, but that 274 
this effect is uncertain for women over 40 years old. 275 
 276 
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Figures legends 375 
 376 
Figure 1. Consort diagram showing disposition of patients recruited. 377 
 378 
Figure 2. Hormonal evaluation.   Blue, Control group; red, Goserelin group, data are shown as 379 
mean± sem. Note that AMH is shown on a log10 scale to allow the very low concentrations 380 
during and post chemotherapy to be more clearly shown. EoT: end of chemotherapy treatment. 381 
* P = 0.027, P = 0.001 vs control group at 12 and 24 months respectively. Sample size for 382 
Control group 59-107 for FSH, LH, E2 and 37-56 for AMH; for Goserelin group, 63-96 and 36-383 
53 respectively. 384 
